Your browser doesn't support javascript.
loading
Active surveillance versus initial surgery in the long-term management of Bosniak IIF-IV cystic renal masses.
Luomala, Lassi; Rautiola, Juhana; Järvinen, Petrus; Mirtti, Tuomas; Nisén, Harry.
Afiliação
  • Luomala L; Department of Urology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. lassi.luomala@hus.fi.
  • Rautiola J; Department of Urology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
  • Järvinen P; Department of Urology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
  • Mirtti T; HUSLAB Laboratory Services and Research Program in Systemic Oncology, Diagnostic Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
  • Nisén H; Research Program in Systemic Oncology, University of Helsinki, Helsinki, Finland.
Sci Rep ; 12(1): 10184, 2022 06 17.
Article em En | MEDLINE | ID: mdl-35715428
ABSTRACT
There may be surgical overtreatment of complex cystic renal masses (CRM). Growing evidence supports active surveillance (AS) for the management for Bosniak IIF-III CRMs. We aimed to evaluate and compare oncological and pathological outcomes of Bosniak IIF-IV CRMs treated by initial surgery (IS) or AS. We identified retrospectively 532 patients with CRM counseled during 2006-2017. IS and AS were delivered to, respectively, 1 and 286 patients in Bosniak IIF, to 54 and 85 patients in III and to 85 and 21 patients in Bosniak IV. Median follow-up was 66 months (IQR 50-96). Metastatic progression occurred for 1 (0.3%) AS patient in Bosniak IIF, 1 IS (1.8%) and 1 AS (1.2%) patient in Bosniak III and 5 IS (3.5%) patients in Bosniak IV, respectively. Overall 5-year metastasis-free survival was 98.9% and cancer-specific survival was 99.6% without statistically significant difference between IS and AS in Bosniak IIF-IV categories. AS did not increase the risk of metastatic spread or cancer-specific mortality in patients with Bosniak IIF-IV. Our data indicate AS in Bosniak IIF and III is safe. Surgery is the primary treatment for Bosniak IV due to its high malignancy rate.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Renais Císticas / Neoplasias Renais Tipo de estudo: Observational_studies / Risk_factors_studies / Screening_studies Limite: Humans Idioma: En Revista: Sci Rep Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Finlândia

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Renais Císticas / Neoplasias Renais Tipo de estudo: Observational_studies / Risk_factors_studies / Screening_studies Limite: Humans Idioma: En Revista: Sci Rep Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Finlândia